Table 2 Overview of questionnaire, and treatment data of the patients that participated both at baseline and follow-up
No. of subjects | Baseline | Follow-up | ||
|---|---|---|---|---|
Non-NPSLE | NPSLE | Non-NPSLE | NPSLE | |
22 | 30 | 22 | 30 | |
Age range (median) | 18–51 (34.5) | 18–49 (41) | 23–56 (38.5) | 22–55 (44) |
Disease duration (years) | 13.0 (1.0–24.0) | 10.0 (1.0–24.0) | 17.2 (5.1–27.7) | 14.6 (4.5–28.1) |
SDI-score | 0.0 (0.0–1.9) | 0.0 (0.0–3.0) | 0.0 (0.0–1.9) | 1.0 (0.0–4.0) |
SLEDAI-2 k-score | 1.0 (0.0–4.0) | 2.0 (0.0–7.3) | 2.0 (0.0–3.9) | 2.0 (0.0–10.2) |
anti-nuclear antibodies | 22 (100%) | 29 (96%) | 22 (100%) | 28 (93%) |
anti-ds-DNA antibodies | 12 (54%) | 18 (60%) | 12 (54%) | 18 (60%) |
anti Sm-nuclear antigen | 4 (18%) | 4 (13%) | 4 (18%) | 3 (10%) |
Glucocorticoids | 17 (77%) | 25 (83%) | 13 (59%) | 19 (63%) |
Daily dose of glucocorticoids | 4.5 (0.0–14.7) | 5.0 (0.0–12.7) | 2.0 (0.0–10.0) | 5.0 (0.0–10.0) |
Antimalarials | 20 (90%) | 23 (76%) | 19 (86%) | 22 (73%) |
Cyclophosphamide | 1 (4%) | 0 (0%) | 0 (0%) | 0 (0%) |
Azathioprine | 9 (40%) | 11 (36%) | 2 (9%) | 11 (36%) |
Cyclosporine A | 0 (0%) | 0 (0%) | 2 (9%) | 0 (0%) |
MMF | 3 (13%) | 6 (20%) | 2 (9%) | 5 (16%) |
Rituximab | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3%) |
IVIG | 1 (4%) | 1 (3%) | 1 (4%) | 1 (3%) |
Methotrexate | 1 (4%) | 0 (0%) | 1 (4%) | 3 (10%) |
Belimumab | 5 (22%) | 2 (6%) | 7 (31%) | 3 (10%) |
Antihypertensive treatment | 5 (22%) | 9 (30%) | 3 (13%) | 9 (30%) |
aPL+ | 5 (22%) | 13 (45%) | ||